Recent proposals from the Office of Management and Budget (OMB) have ignited fierce debates regarding federal grant rules and funding decisions. Critics argue that these changes could undermine scientific research by politicizing funding criteria and placing political goals above objective standards. Various stakeholders, including scientists and research institutions, warn that the proposed regulations could lead to a significant reduction in the number of clinical trials and jeopardize important research initiatives across the country. The uncertainty surrounding these potential rule changes has prompted calls for extended public comment periods and legislative actions to block such initiatives. As discussions continue, the scientific community remains vigilant, asserting that research should remain apolitical and not subject to the whims of political appointees.